Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers

Fig. 6

Cell cycle analysis of A MCF7 and B MCF7/ADR cells after treatment with docetaxel (DTX)- or curcumin (CUR)-loaded formulations at 100 ng/mL DTX-equivalent concentration (DTX:CUR = 1:3, w/w) for 24 h. Data represent FACS histogram of the cell cycle (left panel) and quantification of cell cycle arrest (right panel) of MCF7 and MCF7/ADR cells

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us